Amgen, Inc.

Roflumilast cream 0.15% showed high efficacy in treating mild to moderate atopic dermatitis in patients aged 6 years and older, with more patients achieving a validated IGA-AD score of 0/1 and minimal application site irritation.

Autolus Therapeutics' Aucatzyl, a CAR T-cell therapy targeting CD19, received FDA approval for treating adult B-cell precursor acute lymphoblastic leukemia (ALL). Aucatzyl differentiates itself with faster off-rate and lower complication rates, potentially improving safety and durability. The therapy's approval is based on a trial showing 42% complete remission within three months. Aucatzyl enters a market dominated by Amgen's Blincyto and Gilead's Tecartus, with potential for $300 million in peak sales.

TEZSPIRE (tezepelumab) showed significant reduction in nasal polyp size and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering potential new treatment.

AstraZeneca and Amgen's Tezspire, approved for severe asthma, showed reduction in nasal polyp size and improved congestion in Phase III, potentially leading to a second indication.

The article discusses the importance of enabling JavaScript for optimal app performance.

AstraZeneca and Amgen's Tezspire showed efficacy in reducing nasal congestion and nasal polyps in a Phase 3 trial for chronic rhinosinusitis. Jazz Pharmaceuticals plans to start an early-stage study for narcolepsy treatment JZP441 in 2024. Geron secured $250 million, potentially $375 million, for its myelofibrosis drug Rytelo. Aditum Bio and Leads Biolabs formed Oblenio Bio to develop a T cell engager for autoimmune diseases. Gilead Sciences halted Trodelvy development in second-line non-small cell lung cancer, resulting in a $1.8 billion write-down. Avid Bioservices is being taken private by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion deal.

The Phase III WAYPOINT trial showed AstraZeneca and Amgen’s Tezspire significantly reduced nasal polyp size and congestion in chronic rhinosinusitis patients, offering a potential new treatment option.

AstraZeneca and Amgen's Phase III trial of Tezspire showed significant reduction in nasal polyp size and congestion in chronic rhinosinusitis with nasal polyps patients, offering a new treatment option.

AstraZeneca and Amgen's Tezspire met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion. Tezspire, a TSLP inhibiting monoclonal antibody, also received FDA breakthrough therapy designation for COPD. The therapy competes with Sanofi and Regeneron's Dupixent, which generated €10.7bn in sales in 2022. Both Tezspire and Dupixent are projected to see increased sales by 2030.